Cargando…

Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma

The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 random...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wei, Fu, Di, Shi, Qing, Dong, Lei, Yi, Hongmei, Huang, Hengye, Jiang, Xufeng, Song, Qi, Liu, Zhenhua, Cheng, Shu, Huang, Jinyan, Wang, Li, Xu, Pengpeng, Zhao, Weili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454464/
https://www.ncbi.nlm.nih.gov/pubmed/34557402
http://dx.doi.org/10.3389/fonc.2021.638757
_version_ 1784570497263992832
author Qin, Wei
Fu, Di
Shi, Qing
Dong, Lei
Yi, Hongmei
Huang, Hengye
Jiang, Xufeng
Song, Qi
Liu, Zhenhua
Cheng, Shu
Huang, Jinyan
Wang, Li
Xu, Pengpeng
Zhao, Weili
author_facet Qin, Wei
Fu, Di
Shi, Qing
Dong, Lei
Yi, Hongmei
Huang, Hengye
Jiang, Xufeng
Song, Qi
Liu, Zhenhua
Cheng, Shu
Huang, Jinyan
Wang, Li
Xu, Pengpeng
Zhao, Weili
author_sort Qin, Wei
collection PubMed
description The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 randomized trial NHL-001 (NCT01852435) were reviewed. Meanwhile, genetic aberrations, gene expression pattern, and tumor immunophenotype profile were revealed by DNA and RNA sequencing of 116 and 53 patients, respectively. SE patients showed similar clinicopathological features as SN patients, except for an increased percentage of low-intermediate risk in the National Comprehensive Cancer Network–International Prognostic Index. According to the molecular features, increased MPEG1 mutations were observed in SN patients, while SE patients were associated with upregulation of TGF-β signaling pathway and downregulation of T-cell receptor signaling pathway. SE patients also presented immunosuppressive status with lower activity of killing of cancer cells and recruiting dendritic cells. Extranodal involvement had no influence on progression-free survival (PFS) or overall survival (OS) in localized DLBCL. Serum lactate dehydrogenase >3 upper limit of normal was an independent adverse prognostic factor for OS, and ATM mutations were related to inferior PFS. Although the overall prognosis is satisfactory, specific clinical, genetic, and microenvironmental factors should be considered for future personalized treatment in localized DLBCL.
format Online
Article
Text
id pubmed-8454464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84544642021-09-22 Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma Qin, Wei Fu, Di Shi, Qing Dong, Lei Yi, Hongmei Huang, Hengye Jiang, Xufeng Song, Qi Liu, Zhenhua Cheng, Shu Huang, Jinyan Wang, Li Xu, Pengpeng Zhao, Weili Front Oncol Oncology The clinical and molecular characteristics of localized diffuse large B-cell lymphoma (DLBCL) with single nodal (SN) or single extranodal (SE) involvement remain largely elusive in the rituximab era. The clinical data of 181 patients from a retrospective cohort and 108 patients from a phase 3 randomized trial NHL-001 (NCT01852435) were reviewed. Meanwhile, genetic aberrations, gene expression pattern, and tumor immunophenotype profile were revealed by DNA and RNA sequencing of 116 and 53 patients, respectively. SE patients showed similar clinicopathological features as SN patients, except for an increased percentage of low-intermediate risk in the National Comprehensive Cancer Network–International Prognostic Index. According to the molecular features, increased MPEG1 mutations were observed in SN patients, while SE patients were associated with upregulation of TGF-β signaling pathway and downregulation of T-cell receptor signaling pathway. SE patients also presented immunosuppressive status with lower activity of killing of cancer cells and recruiting dendritic cells. Extranodal involvement had no influence on progression-free survival (PFS) or overall survival (OS) in localized DLBCL. Serum lactate dehydrogenase >3 upper limit of normal was an independent adverse prognostic factor for OS, and ATM mutations were related to inferior PFS. Although the overall prognosis is satisfactory, specific clinical, genetic, and microenvironmental factors should be considered for future personalized treatment in localized DLBCL. Frontiers Media S.A. 2021-09-07 /pmc/articles/PMC8454464/ /pubmed/34557402 http://dx.doi.org/10.3389/fonc.2021.638757 Text en Copyright © 2021 Qin, Fu, Shi, Dong, Yi, Huang, Jiang, Song, Liu, Cheng, Huang, Wang, Xu and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Qin, Wei
Fu, Di
Shi, Qing
Dong, Lei
Yi, Hongmei
Huang, Hengye
Jiang, Xufeng
Song, Qi
Liu, Zhenhua
Cheng, Shu
Huang, Jinyan
Wang, Li
Xu, Pengpeng
Zhao, Weili
Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title_full Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title_fullStr Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title_full_unstemmed Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title_short Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma
title_sort molecular heterogeneity in localized diffuse large b-cell lymphoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454464/
https://www.ncbi.nlm.nih.gov/pubmed/34557402
http://dx.doi.org/10.3389/fonc.2021.638757
work_keys_str_mv AT qinwei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT fudi molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT shiqing molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT donglei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT yihongmei molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT huanghengye molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT jiangxufeng molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT songqi molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT liuzhenhua molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT chengshu molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT huangjinyan molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT wangli molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT xupengpeng molecularheterogeneityinlocalizeddiffuselargebcelllymphoma
AT zhaoweili molecularheterogeneityinlocalizeddiffuselargebcelllymphoma